Merck has been buying belongings that might assist make up for the approaching income decline as its high product, the most cancers drug Keytruda, drops off the patent cliff. Terns Prescription drugs’ lead product candidate, in improvement for treating a kind of leukemia, may provide dosing and efficacy benefits over the Novartis drug Scemblix.
The submit Merck’s $6.7B Terns Acquisition Positions It to Problem a Blockbuster Novartis Most cancers Drug appeared first on MedCity Information.
